Dr. Travis D. Ayers, M.D.
Pediatric Gastroenterology (Pediatric Gastroenterology Physician)
At a glance
- Medical school
- Medical University of South Carolina College of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Medical University of South Carolina College of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Gastroenterology Physician primary
AR license E-11301 -
Pediatrics Physician
AR license E-11301
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Arkansas Childrens Professional Services Organization LLC (184 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $23,850 in research payments for these studies, mostly to the institutions running them.
- M16-194 - A Study to Assess Adverse Events Change in Disease Activity and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn s Disease
AbbVie Inc. - Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
AbbVie Inc. · Active, not recruiting · NCT05782907 - A Study to Assess Adverse Events Change in Disease Activity and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn s Disease
AbbVie Inc. - An openlabel singlearm study to evaluate the efficacy pharmacokinetics and safety of etrasimod in adolescent subjects with moderately to severely active ulcerative colitis
Pfizer Inc. - A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
AbbVie Inc. · Recruiting · NCT05995353
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.